$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
[Collection] Xakorui’s 2021 medical insurance reimbursement ratio for those who don’t want to pay for themselves
2025-10-19 11:44:20
Check Details
Interpretation of the 2021 medical insurance policy for Gitairinib (afatinib) Please take 2 minutes to read it
2025-10-19 11:44:20
Check Details
Deciphering the drug properties of Iressa (gefitinib) and who is suitable for using this targeted drug_ Kanghule
2025-10-19 11:44:20
Check Details
What is the effective target of gefitinib? People targeted by lung cancer want to know about the speed points
2025-10-19 11:44:20
Check Details
Do I need to be tested before taking the targeted drug cabozantinib?
2025-10-19 11:44:20
Check Details
【Are you curious】What will happen to your skin after using Gitairinib (afatinib)
2025-10-19 11:44:20
Check Details
up to date! Xakori (Crizotinib) medical insurance reimbursement requirements. If you want to be reimbursed, please click here
2025-10-19 11:44:20
Check Details
How effective is gefitinib in the treatment of locally advanced or metastatic non-small cell lung cancer? See what the experts say
2025-10-19 11:44:20
Check Details
The latest medical insurance reimbursement conditions for the lung cancer targeted drug gefitinib are here, and lung cancer patients are overjoyed
2025-10-19 11:44:20
Check Details
How long does it take to develop drug resistance after taking Giterinib (afatinib)? Expert advice
2025-10-19 11:44:20
Check Details
Data on the efficacy of the targeted drug cabozantinib in the treatment of RET rearranged lung cancer
2025-10-19 11:44:20
Check Details
Increase the reimbursement ratio? The latest interpretation of Jitai Rui’s 2021 medical insurance reimbursement policy
2025-10-19 11:44:20
Check Details
1
2
...
3905
3906
3907
3908
3909
3910
3911
...
4156
4157
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Global Update 2026: Selumetinib (KOSELUGO) Expands Indication to Adult NF1-PN and Clinical Management Strategies
2
Lenvatinib Safety Guide: Baseline Assessment & Adverse Reaction Management
3
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations
4
Idelalisib: Oral PI3Kδ Inhibitor for Relapsed/Refractory Hematologic Malignancies
5
Lorlatinib (Lorviqua): Oral Targeted Therapy for ALK-Positive Advanced Non-Small Cell Lung Cancer
6
FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer
7
FDA Approves Trodelvy for Two First-Line Indications, Redefining Advanced Triple-Negative Breast Cancer Care
8
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice
9
Managing Amivantamab Infusion Reactions: A Clinical Guide for International Practice
10
Onset Timeline and Efficacy Assessment of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer
11
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
12
Vemurafenib (Zelboraf) Complete Medication Guide